ZATA Pharmaceuticals, Inc.
ZATA is developing novel treatments for human diseases using nucleic acid derivatives as potential therapeutic compounds
ZATA’s technology comprises several streams of potential development of therapies based on employment of novel nucleic acid analogs as potential therapeutic agents. ZATA’s patent protected intellectual property includes analogs of the Ap4A family as potential therapeutic agents. Dr. Zamecnik and colleagues discovered the Ap4A family of compounds as natural constituents of all living cells, whose specific biological roles as messenger and metabolic regulators are just now being delineated.
ZATA’s antisense technology has demonstrated promising efficacy for M. Tuberculosis, Influenza and Malaria.
ZATA’s novel dual targeting approach portends enhancement in therapeutics of those and other microbial diseases, plus cancer, particularly human papilloma virus.
ZATA’s current activity also focuses discovery of novel nucleic acid chemistry which could increase stability and delivery rate of single and double stranded oligonucleotides, such as modified siRNA, antisense oligo-DNA and their conjugates plus the small chemical groups which could enhance their stability, permeability into cells and therapeutic efficacy.
